|
|
Article: FDA Approves Efficacy Results for Spine Bone Mineral Density in Childhood-Onset Growth Hormone Deficient Adults.
- Article from:
- Business Wire
- Article date:
- December 2, 1999
CopyrightCOPYRIGHT 1999 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Dec. 2, 1999--
Genentech, Inc. (NYSE: DNA) today announced approval from the U.S. Food and Drug Administration (FDA) of additional efficacy results for its growth hormone products -- Nutropin(R) (somatropin (rDNA origin) for injection) and Nutropin AQ(R) (somatropin (rDNA origin) injection) -- on the effects of growth hormone replacement therapy on spine bone mineral density in young adults with childhood-onset growth hormone deficiency (GHD).
New clinical data show significant increases in spine bone mineral density can be achieved with growth hormone therapy in these growth hormone (GH) deficient young ...